DxVx Co., Ltd.’s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200

DXVX announces that its affiliated company Oxford Vacmedix has completed Phase 1a trial of cancer vaccine and plans to proceed Phase 1b trial of OVM-200.